OTC Markets OTCQB - Delayed Quote USD

Izotropic Corporation (IZOZF)

0.1030

0.0000

(0.00%)

At close: January 14 at 3:00:00 PM EST

Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

-A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch- -Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue--Comprehensive filing includes patient acquisition and clinical study plans that validate a projected clinical study timeline

Newsfile 5 days ago

IZOZF
0.00%
Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting, information circular, requests for financial statements and proxy form (the "Meeting Mat

Newsfile last month

IZOZF
0.00%
Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU

Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a breast CT (computed tomography) imaging system, is pleased to announce that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue, a normal variation associated with an increased risk for devel

Newsfile 4 months ago

IZOZF
0.00%
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 1,800,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of $180,000.00. ...

Newsfile 6 months ago

IZOZF
0.00%
Izotropic Corporation Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. ...

Newsfile 7 months ago

IZOZF
0.00%
Izotropic Receives Response From U.S. FDA

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8th disclosure, it has received a response from the U.S. FDA. The FDA's mammogram and ultrasound

Newsfile 11 months ago

IZOZF
0.00%

Performance Overview

Return	IZOZF	S&P/TSX Composite index
YTD	+243.33%	-0.13%
1-Year	-23.13%	+17.14%
3-Year	-85.37%	+15.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Izotropic Corporation (IZOZF)

Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening

Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures

Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Izotropic Corporation Announces Non-Brokered Private Placement

Izotropic Receives Response From U.S. FDA

Performance Overview